Project: Development of potent therapeutic bispecific antibodies that enhance tumor immunity

Combine the proprietary technologies of the consortium members to develop one or more bispecific antibodies that specifically target and positively modulate anti-tumor immunity. The project will deliver: > 1 lead bispecific antibody with a pre-clinical proof of concept and research cell bank ready for manufacturing; > 1 antibody screening assay based on unresponsive human T cells that mimics the phenotype of T cells present in the human tumor microenvironment ready for commercialization.

Acronym iMOD-ReACT (Reference Number: 10599)
Duration 15/08/2016 - 01/08/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24624 Merus BV Coordinator Netherlands
24625 Aquila BioMedical Ltd Partner United Kingdom